Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bloody diarrhea

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Bloody diarrhea. Displaying page 1 of 1.
    EudraCT Number: 2011-006094-26 Sponsor Protocol Number: CTP_STX005/STX005EXT Start Date*: 2012-02-10
    Sponsor Name:Thallion Pharmaceuticals Inc
    Full Title: A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (caStx1) and 2 (caStx2) Administered Concomitantly to Children with Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody ...
    Medical condition: Prevention of Shiga toxin-mediated complications resulting from Shiga toxin producing bacterial infections.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10019515 Hemolytic uremic syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2012-002291-13 Sponsor Protocol Number: DIALAGG Start Date*: 2012-10-19
    Sponsor Name:InfectoPharm - Arzneimittel und Consilium GmbH
    Full Title: Multicentre, prospective, double-blind, two-armed, placebo-controlled phase III study to evaluate the efficacy and safety of the treatment of diarrhoea with Lactobacillus rhamnosus GG (InfectoDiarr...
    Medical condition: Acute diarrhoea in infants and toddlers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10000706 Acute diarrhea LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005700-15 Sponsor Protocol Number: marha1983 Start Date*: 2013-01-07
    Sponsor Name:Lennart Svensson Linköping University Medical Faculty
    Full Title: Can 5-HT3 receptor antagonists be used to limit vomiting in rota- and norovirus infections?
    Medical condition: Virus caused vomiting and effect of the antiemetic drug Ondansetron
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002923-24 Sponsor Protocol Number: R033812GTS3001 Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects Wi...
    Medical condition: Nausea and Vomiting Due to Acute Gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10066762 Acute gastroenteritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PT (Completed) BE (Completed) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007952-90 Sponsor Protocol Number: LT-02-UC-01 Start Date*: 2009-11-17
    Sponsor Name:Lipid Therapeutics GmbH
    Full Title: A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulce...
    Medical condition: Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) ≥5 and SCCAI subscore for “blood in sto...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002784-91 Sponsor Protocol Number: HAW0501 Start Date*: 2006-02-06
    Sponsor Name:Cardiff and Vale NHS Trust
    Full Title: A Randomized, Multicentre, Parallel Group Single-Blind Study to Assess the Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily versus Divided Doses Three Times Dai...
    Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-002751-19 Sponsor Protocol Number: 82160 Start Date*: 2023-04-11
    Sponsor Name:Amsterdam UMC
    Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients
    Medical condition: Inflammatory Bowel Diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004077-29 Sponsor Protocol Number: 2004112 Start Date*: 2005-02-04
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Double-blind, Randomized, Multicenter, Active-control, 56-day Study with a 28-day Follow-up to Assess the Efficacy and Safety of RDP58 200 mg/day plus Mesalazine 2.4 g/day and RDP58 600 mg/day pl...
    Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) SK (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000092-37 Sponsor Protocol Number: PR200-103 Start Date*: 2021-11-03
    Sponsor Name:Prometheus Biosciences, Inc. a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004997-32 Sponsor Protocol Number: GA40209 Start Date*: 2018-12-10
    Sponsor Name:Roche Farma, S.A por delegación de Genentech, Inc.
    Full Title: A PHASE II OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE
    Medical condition: Ulcerative Colitis (UC) or Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10033007 Other ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    20.0 100000004856 10075635 Acute hemorrhagic ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) IE (Prematurely Ended) DE (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002350-36 Sponsor Protocol Number: GA39925 Start Date*: 2018-09-27
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO A...
    Medical condition: Ulcerative colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10033007 Other ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    20.0 100000004856 10075635 Acute hemorrhagic ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IE (Completed) HU (Completed) NL (Completed) BG (Completed) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000091-11 Sponsor Protocol Number: PR200-102 Start Date*: 2021-09-21
    Sponsor Name:Prometheus Biosciences, Inc.
    Full Title: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Activ...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001760-30 Sponsor Protocol Number: CB8025-21845 Start Date*: 2019-10-11
    Sponsor Name:CymaBay Therapeutics
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients with Prima...
    Medical condition: Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease that is characterized by diffuse inflammation and fibrosis of the bile ducts. The intra and/or extrahepatic bile ducts ca...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002833-13 Sponsor Protocol Number: AMT-101-203 Start Date*: 2021-02-05
    Sponsor Name:Applied Molecular Transport Inc.
    Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Sev...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000047-31 Sponsor Protocol Number: AMT-101-202 Start Date*: 2020-08-03
    Sponsor Name:Applied Molecular Transport Inc.
    Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) DE (Completed) BG (Completed) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002981-64 Sponsor Protocol Number: CC-10004-UC-001 Start Date*: 2015-08-13
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS
    Medical condition: Subjects with active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003392-30 Sponsor Protocol Number: 15-0106 Start Date*: 2016-04-18
    Sponsor Name:NGM Biopharmaceuticals, Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WIT...
    Medical condition: PRIMARY SCLEROSING CHOLANGITIS (PSC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10019805 - Hepatobiliary disorders 10036732 Primary sclerosing cholangitis LLT
    19.0 10019805 - Hepatobiliary disorders 10004607 Bile duct infections and inflammations HLT
    19.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    19.0 10019805 - Hepatobiliary disorders 10008609 Cholangitis sclerosing PT
    19.0 10019805 - Hepatobiliary disorders 10004606 Bile duct disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000236-22 Sponsor Protocol Number: Study_protocol_CODEX-P_ver2_1 Start Date*: 2020-12-16
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD EXacerbation and Pulmonary hypertension Trial - The effect of Sildenafil treatment to patients with COPD exacerbation and pulmonary hypertension
    Medical condition: This study will investigate treatment of patients with chronic obstructive pulmonary disease (COPD), who experience frequent exacerbations (AECOPD). Only patients with a minimum of 2 moderate AECOP...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10019203 Head spinning LLT
    20.1 100000004852 10033405 Pain head LLT
    20.0 100000004852 10019218 Headache NOS LLT
    20.1 100000004856 10000460 Acid dyspepsia LLT
    22.1 100000004856 10013947 Dyspepsia aggravated LLT
    20.0 100000004856 10013948 Dyspepsia and other specified disorders of function of stomach LLT
    21.1 100000004856 10019328 Heartburn-like dyspepsia LLT
    20.1 100000004856 10064536 Functional dyspepsia LLT
    23.1 100000004856 10012727 Diarrhea LLT
    20.0 100000004859 10023222 Joint pain LLT
    21.0 100000004859 10025012 Lumbo-sacral pain LLT
    21.1 100000004859 10028322 Muscle pain LLT
    20.0 100000004856 10033394 Pain epigastric LLT
    21.1 100000004866 10016046 Facial flushing LLT
    20.0 100000004853 10013614 Double vision LLT
    21.0 100000004848 10005604 Blood in urine LLT
    20.0 100000004872 10018801 Gynecomastia LLT
    20.0 100000004872 10060603 Hematospermia LLT
    20.0 100000004851 10002272 Anemia LLT
    22.1 100000004853 10034961 Photophobia aggravated LLT
    20.0 100000004871 10023139 Jaundice NOS LLT
    20.0 100000004853 10030042 Ocular hyperemia LLT
    20.1 100000004853 10051304 Retinal bleeding LLT
    20.1 100000004853 10005889 Blurry vision LLT
    20.1 100000004856 10046272 Upper abdominal pain LLT
    20.0 100000004856 10038263 Reflux oesophagitis LLT
    20.0 100000004856 10047706 Vomiting NOS LLT
    20.0 100000004867 10016558 Fever LLT
    21.1 100000004862 10024969 Lower respiratory tract infection NOS LLT
    20.0 100000004859 10048317 Myalgia aggravated LLT
    21.1 100000004859 10003990 Back pain (without radiation) LLT
    20.1 100000004852 10020922 Hypesthesia LLT
    20.0 100000004852 10027605 Migraine NOS LLT
    21.1 100000004852 10044572 Tremor limb LLT
    20.1 100000004852 10044570 Tremor finger LLT
    20.0 100000004873 10002856 Anxiety attack LLT
    20.0 100000004873 10022442 Insomnia NOS LLT
    20.0 100000004855 10011232 Coughing LLT
    20.0 100000004862 10040756 Sinusitis NOS LLT
    20.0 100000004867 10014210 Edema LLT
    20.0 100000004867 10014211 Edema (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 09:53:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA